Cargando…

Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma

INTRODUCTION: Disease spectrum of upper tract transitional cell carcinoma (TCC) in Indian patients is not known. Herein, we present data on clinical presentation, pathological characteristics, and the outcome of treatment of upper tract TCC. MATERIALS AND METHODS: Clinicopathological data of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Radhakrishnan, Surdas, Aga, Pallavi, Jain, Manoj, Srivastava, Aneesh, Kapoor, Rakesh, Mandhani, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424894/
https://www.ncbi.nlm.nih.gov/pubmed/22919133
http://dx.doi.org/10.4103/0970-1591.98460
_version_ 1782241282620391424
author Radhakrishnan, Surdas
Aga, Pallavi
Jain, Manoj
Srivastava, Aneesh
Kapoor, Rakesh
Mandhani, Anil
author_facet Radhakrishnan, Surdas
Aga, Pallavi
Jain, Manoj
Srivastava, Aneesh
Kapoor, Rakesh
Mandhani, Anil
author_sort Radhakrishnan, Surdas
collection PubMed
description INTRODUCTION: Disease spectrum of upper tract transitional cell carcinoma (TCC) in Indian patients is not known. Herein, we present data on clinical presentation, pathological characteristics, and the outcome of treatment of upper tract TCC. MATERIALS AND METHODS: Clinicopathological data of patients who were diagnosed for upper tract TCC between January 2000 and January 2010 were collected from the hospital information system and case records. Preoperative diagnosis was based on contrast-enhanced computerized tomography of the whole abdomen and urine cytology. Cross tab and logistic regression analysis was done on the effect of various clinicopathological characteristics on the outcome and cancer-specific and recurrence survival were derived. RESULTS: There were total 40 patients, 35 (87.5%) of them were male. The mean age was 62.7 ± 7.9 years. The most common symptom was gross hematuria present in 30 (75%). Mean tumor size was 2.8 ± 1.2 cm. Median duration of follow up was 36 (12 to 100) months. Laparoscopic nephroureterectomy was done in 27 patients along with bladder cuff excision and seven patients underwent open surgery. Thirty two (88.8%) patients had invasive T stage and high-grade lesions were seen in 24 (66.6%). Lymphovascular invasion was found only in one case and necrosis in 30 (83.3%). Necrosis was found to be the poor prognostic factor. Five-year recurrence-free and cancer-specific survivals were 36.33% and 26%, respectively. CONCLUSION: Patients with upper tract TCC present very late with a high-stage disease and a very low 5-year cancer-specific and recurrence-free survivals.
format Online
Article
Text
id pubmed-3424894
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-34248942012-08-23 Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma Radhakrishnan, Surdas Aga, Pallavi Jain, Manoj Srivastava, Aneesh Kapoor, Rakesh Mandhani, Anil Indian J Urol Original Article INTRODUCTION: Disease spectrum of upper tract transitional cell carcinoma (TCC) in Indian patients is not known. Herein, we present data on clinical presentation, pathological characteristics, and the outcome of treatment of upper tract TCC. MATERIALS AND METHODS: Clinicopathological data of patients who were diagnosed for upper tract TCC between January 2000 and January 2010 were collected from the hospital information system and case records. Preoperative diagnosis was based on contrast-enhanced computerized tomography of the whole abdomen and urine cytology. Cross tab and logistic regression analysis was done on the effect of various clinicopathological characteristics on the outcome and cancer-specific and recurrence survival were derived. RESULTS: There were total 40 patients, 35 (87.5%) of them were male. The mean age was 62.7 ± 7.9 years. The most common symptom was gross hematuria present in 30 (75%). Mean tumor size was 2.8 ± 1.2 cm. Median duration of follow up was 36 (12 to 100) months. Laparoscopic nephroureterectomy was done in 27 patients along with bladder cuff excision and seven patients underwent open surgery. Thirty two (88.8%) patients had invasive T stage and high-grade lesions were seen in 24 (66.6%). Lymphovascular invasion was found only in one case and necrosis in 30 (83.3%). Necrosis was found to be the poor prognostic factor. Five-year recurrence-free and cancer-specific survivals were 36.33% and 26%, respectively. CONCLUSION: Patients with upper tract TCC present very late with a high-stage disease and a very low 5-year cancer-specific and recurrence-free survivals. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3424894/ /pubmed/22919133 http://dx.doi.org/10.4103/0970-1591.98460 Text en Copyright: © Indian Journal of Urology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Radhakrishnan, Surdas
Aga, Pallavi
Jain, Manoj
Srivastava, Aneesh
Kapoor, Rakesh
Mandhani, Anil
Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma
title Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma
title_full Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma
title_fullStr Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma
title_full_unstemmed Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma
title_short Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma
title_sort clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424894/
https://www.ncbi.nlm.nih.gov/pubmed/22919133
http://dx.doi.org/10.4103/0970-1591.98460
work_keys_str_mv AT radhakrishnansurdas clinicopathologicalspectrumandtheoutcomeoftreatmentofuppertracttransitionalcellcarcinoma
AT agapallavi clinicopathologicalspectrumandtheoutcomeoftreatmentofuppertracttransitionalcellcarcinoma
AT jainmanoj clinicopathologicalspectrumandtheoutcomeoftreatmentofuppertracttransitionalcellcarcinoma
AT srivastavaaneesh clinicopathologicalspectrumandtheoutcomeoftreatmentofuppertracttransitionalcellcarcinoma
AT kapoorrakesh clinicopathologicalspectrumandtheoutcomeoftreatmentofuppertracttransitionalcellcarcinoma
AT mandhanianil clinicopathologicalspectrumandtheoutcomeoftreatmentofuppertracttransitionalcellcarcinoma